Effectiveness, Safety, and Adherence to Treatment of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Real Practice.
Gayoso-Rey M, Díaz-Trastoy O, Romero-Ventosa EY, García-Beloso N, González-Freire L, Lorenzo-Lorenzo K, Mantiñán-Gil B, Palmeiro-Carballeira R, Bravo-Amaro M, López-Gil-Otero MDM, Martínez-Reglero C, Crespo-Diz C, Fernández-Catalina P, Piñeiro Corrales G.
Gayoso-Rey M, et al. Among authors: martinez reglero c.
Clin Ther. 2021 Apr;43(4):e111-e121. doi: 10.1016/j.clinthera.2021.02.002. Epub 2021 Mar 9.
Clin Ther. 2021.
PMID: 33712271